Drug-Coated Balloon Treatment as Default Strategy for DES-ISR  by Scheller, Bruno et al.
Letters J A C C V O L . 6 7 , N O . 3 , 2 0 1 6
J A N U A R Y 2 6 , 2 0 1 6 : 3 4 3 – 5 2
346infusion and underwent angiography at 1 year
follow-up, corresponding rates were 28.7% and
21.4%, respectively (adjusted OR: 0.67; 95% CI: 0.40
to 1.13; p ¼ 0.14). Differences between placebo and
inclacumab groups for all pre-speciﬁed secondary
efﬁcacy measures were not statistically signiﬁcant
(Table 1). 13.9% and 14.2% of patients in the placebo
and inclacumab groups had $1 reported major
adverse cardiovascular event (p ¼ 0.88) (Table 1).
There were no apparent inclacumab-induced effects
on bleeding events.
Post hoc analyses showed an interaction between
the plasma soluble P-selectin level at baseline and
the treatment arm on the primary efﬁcacy measure
(p ¼ 0.053). In patients with baseline P-selectin levels
above the median, the primary efﬁcacy measure
tended to be reduced in the inclacumab (12.8%)
as compared to the placebo group (27.8%; adjusted
OR: 0.37; 95% CI: 0.12 to 1.15; p ¼ 0.085), while this
trend was not observed in patients with baseline
levels below the median (27.0% in the inclacumab vs.
19.1% in the placebo group; adjusted OR: 1.69; 95% CI:
0.60 to 4.77; p ¼ 0.33).
This SELECT-CABG study showed that the speciﬁc
anti-P-selectin antibody inclacumab did not exert
signiﬁcant favorable effects on SVG disease progres-
sion. Given these results, it is possible that the
P-selectin pathway plays an overall less important
role in the pathogenesis of venous graft failure
than previously hypothesized. However, a post hoc
analysis suggested that the pre-existing level of
activation of the P-selectin pathway may determine
the response to inclacumab, a ﬁnding that needs to be
evaluated prospectively.Barbara E. Stähli, MD
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Treatment as Default
Strategy for DES-ISRWe read with interest the publication of RIBS
IV (Restenosis Intra-stent of Bare Metal Stents:
Paclitaxel-eluting Balloon vs Everolimus-eluting
Stent) trial by Alfonso et al. (1), questioning the role
of drug-coated balloons (DCB) in the treatment of
drug-eluting stent restenosis (DES-ISR).
The use of DCB and bioresorbable scaffolds not
only reduces vessel occlusion but serves to promote
vascular healing by leaving no permanent implant
within the vessels. To obtain the full beneﬁt of such
treatment, optimal lesion preparation is crucial (2).
When starting a DCB program, a learning curve
is inevitable, addressing factors like handling the
device, geographical mismatch, and knowledge of
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347conventional angioplasty. We appreciate the long
history of ISR treatment of the RIBS study group.
However the number of patients treated with DCB
in most centers was low.
Furthermore, according to protocol, a residual
stenosis of up to 50% was deﬁned as angiographic
success, and according to the Central Illustration (1),
at least 10% of the patients received DCB despite
>30% residual stenosis after predilation. In line,
inﬂation pressures were signiﬁcantly lower in the
DCB group. Thus, some of the patients may have
almost fulﬁlled the criteria for a restenosis just at
baseline. In contrast, the most accepted recom-
mendation for use of the DCB is a residual stenosis
of less than 30% (2). Also, by protocol advice, pa-
tients in the EES group received another high-
pressure post dilatation. These factors may explain
the poor acute gains in the DCB groups of RIBS V
and IV that were 1.1 and 1.3 mm, respectively (1,3).
By comparison, acute gains in other randomized
DCB trials for ISR treatment were between 1.5 and
1.8 mm, comparing well to the EES group in RIBS
IV (1).
Another concern is drug loss in blood during
passage of DCB to the lesion. In RIBS IV, 5 patients
crossed over from the DCB arm to stenting, meaning
that in an incidence of 3.2% placement of the DCB
was unsuccessful within due time (1), a rate much
lower than that expected even in experienced
high-volume DCB centers.
The difference in major adverse cardiac events
was driven by the higher TLR (target lesion rein-
tervention rate) seen in the DCB group. In the EES
group, 47% of the repeated ISR lesions underwent
TLR but 74% in the DCB group (1). Why do oper-
ators more readily retreat an ISR in the case of
prior DCB but not in the presence of another layer
of metal? In a recent paper, the authors gave the
most likely explanation: “There is a possibility,
however, that the indication for re-interventions at
follow-up would have been inﬂuenced by their
perceived risk beneﬁt. Treating recurrent ISR in
patients with a double metal layer [.] might be
considered as less attractive than treating ISR after
BA failure” (4).
Ironically, this major advantage of DCB, namely
the repeatability of the procedure, leads to a sig-
niﬁcant disadvantage in endpoints that includes
surrogates like TLR and not hard endpoints only.
However, randomized comparisons report a long-
term survival beneﬁt for DCB in DES-ISR treat-
ment. At 3 years follow-up in the ISAR DESIRE 3(Efﬁcacy Study of Paclitaxel-eluting Balloon, -Stent
vs. Plain Angioplasty for Drug-eluting Stent
Restenosis), hazard ratio for overall mortality was
0.38 (6.0% vs. 15.3%, respectively; p ¼ 0.02) and
0.27 for cardiac mortality (p ¼ 0.03) in favor of
DCB versus DES. It is important to note, this
mortality beneﬁt was not related to reintervention
rates (5). One reason may be an elevated stent
thrombosis risk in sandwich DES that has also
been shown for newer generation DES.
We see DCB treatment as the default strategy for
DES-ISR because it avoids several layers of metal,
reduces the need for prolonged dual antiplatelet
therapy, allows for repeatability of the procedure,
and apparently positively inﬂuences hard endpoints
on long-term. The disadvantage in angiographic
outcomes could be limited by careful lesion prepa-
ration assuring sufﬁcient initial lumen gain.*Bruno Scheller, MD
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